Percutaneous Coronary Intervention in Patients With a History of Gastrointestinal Bleeding (From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium)
Section snippets
Methods
We performed a retrospective analysis using data collected by the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2), a quality improvement consortium that maintains a registry of all patients undergoing PCI at 48 nonfederal hospitals in Michigan.14,15 Briefly, BMC2 collects data from all nonfederal hospitals in Michigan using the National Cardiovascular Data Registry CathPCI data collection form. The registry is further enhanced by the inclusion of novel variables and rigorous
Results
A total of 30,206 patients who underwent PCI at 48 non-federal hospitals in Michigan between January 2013 to March 2018 were linked between the BMC2 clinical registry and the MVC claims-based registry. Of the 30,206 patients who underwent PCI, 342 (1.1%) patients had a history of GIB (Figure 1). Baseline characteristics of the study population are presented in Table 1.
In the unmatched cohort, a history of GIB was significantly associated with increased rates of in-hospital death (5% vs 1.4%; p
Discussion
The main finding of this study is that a history of GIB prior to PCI was associated with a higher rate of post-PCI in-hospital bleeding complications including the need for transfusion. Although identified in only 1.1% of >30,000 patients undergoing PCI during this study, a history of GIB was associated with significantly higher risk of in-hospital post-PCI bleeding events. Patients with a history of GIB also had a high rate of 90-day readmission and mortality; however, after adjusting for
Disclosures
Dr. Sukul, Mr. Seth, and Ms. Yaser receive salary support from the Blue Cross Blue Shield of Michigan. Dr. Gurm receives research support from Blue Cross and Blue Shield of Michigan, and Michigan Translational Research and Commercialization for Life Sciences Innovation Hub. He is the co-founder of, owns equity in, and is a consultant to Amplitude Vascular Systems. He also owns equity in Jiaxing Bossh Medical Technology Partnership and is a consultant for Osprey Medical. He is the chair of the
Acknowledgments
The authors are indebted to all the study coordinators, investigators and patients who participated in the BMC2 registry. All authors listed meet the authorship criteria according to the latest guidelines of the International Committee of Medical Journal Editors and all authors agree with the manuscript.
References (23)
- et al.
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease
J Am Coll Cardiol
(2016) - et al.
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the clopidogrel for the reduction of events during observation (CREDO) trial
Am Heart J
(2009) - et al.
Temporal trends, predictors, and outcomes of in-hospital gastrointestinal bleeding associated with percutaneous coronary intervention
Am J Cardiol
(2016) - et al.
Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction
Am J Cardiol
(2005) - et al.
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use
J Am Coll Cardiol
(2010) - et al.
2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease
J Am Coll Cardiol
(2021) - et al.
Heart disease and stroke statistics—2019 update: a report from the American Heart Association
Circulation
(2019) - et al.
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)
Eur Heart J
(2017) - et al.
Predictors and consequences of postdischarge gastrointestinal bleeding after percutaneous coronary intervention
Cardiovasc Ther
(2018) - et al.
Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions
Circ Cardiovasc Interv
(2015)
Inpatient outcomes for gastrointestinal bleeding associated with percutaneous coronary intervention
J Clin Gastroenterol
Cited by (1)
Effect of Gastrointestinal Hemorrhage on Outcome After Endovascular Treatment in Acute Basilar Artery Occlusion
2022, Frontiers in Neurology
Funding: This work was supported by the Blue Cross Blue Shield of Michigan and Blue Care Network as part of the Blue Cross Blue Shield of Michigan Value Partnerships program. The funding source supported data collection and the data coordinating center but had no role in the study concept, interpretation of findings, preparation, final approval, or decision to submit the manuscript.